NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
NewAmsterdam Pharma (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company focused on developing oral, non-statin treatments for cardiovascular disease (CVD) patients with high LDL-C, announced its participation in upcoming investor conferences in September.
Management will attend the Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on September 5-6, 2024. CFO Ian Somaiya will meet 1x1 with investors on September 5th and participate in a fireside chat on September 6th at 10:00 a.m. ET.
The company will also be present at the Cantor Global Healthcare Conference in New York City on September 17, 2024. CEO Michael Davidson, M.D., and CFO Ian Somaiya will participate in a fireside chat at 3:40 p.m. ET.
Live webcasts of both events will be available on the NewAmsterdam Pharma investor relations page, with replays accessible afterward.
NewAmsterdam Pharma (Nasdaq: NAMS), un'azienda biofarmaceutica clinica in fase avanzata focalizzata sullo sviluppo di trattamenti orali non statinici per pazienti affetti da malattie cardiovascolari (CVD) con elevati livelli di LDL-C, ha annunciato la sua partecipazione a conferenze per investitori che si terranno a settembre.
Il management parteciperà alla 22ª Conferenza Globale sulla Salute di Morgan Stanley a New York City il 5-6 settembre 2024. Il CFO Ian Somaiya incontrerà gli investitori individualmente il 5 settembre e parteciperà a una chiacchierata accanto al fuoco il 6 settembre alle 10:00 ET.
L'azienda sarà inoltre presente alla Conferenza Globale sulla Salute di Cantor a New York City il 17 settembre 2024. Il CEO Michael Davidson, M.D., e il CFO Ian Somaiya parteciperanno a una chiacchierata accanto al fuoco alle 15:40 ET.
Le dirette streaming di entrambi gli eventi saranno disponibili sulla pagina delle relazioni con gli investitori di NewAmsterdam Pharma, con riproduzioni accessibili successivamente.
NewAmsterdam Pharma (Nasdaq: NAMS), una compañía biofarmacéutica en etapa avanzada centrada en desarrollar tratamientos orales no estatínicos para pacientes con enfermedades cardiovasculares (CVD) que tienen altos niveles de LDL-C, anunció su participación en conferencias para inversores que se llevarán a cabo en septiembre.
La dirección asistirá a la 22ª Conferencia Anual Global de Salud de Morgan Stanley en Nueva York del 5 al 6 de septiembre de 2024. El CFO Ian Somaiya se reunirá individualmente con los inversores el 5 de septiembre y participará en una charla junto al fuego el 6 de septiembre a las 10:00 a.m. ET.
La empresa también estará presente en la Conferencia Global de Salud de Cantor en Nueva York el 17 de septiembre de 2024. El CEO Michael Davidson, M.D., y el CFO Ian Somaiya participarán en una charla junto al fuego a las 3:40 p.m. ET.
Las transmissiones en vivo de ambos eventos estarán disponibles en la página de relaciones con los inversores de NewAmsterdam Pharma, con repeticiones accesibles posteriormente.
NewAmsterdam Pharma (Nasdaq: NAMS)는 고LDL-C 환자를 위한 경구용 비 스타틴 심혈관 질환(CVD) 치료제 개발에 집중하는 후기 단계의 임상 생명공학 회사로, 9월에 예정된 투자자 회의에 참석한다고 발표했습니다.
경영진은 2024년 9월 5일부터 6일에 뉴욕시에서 열리는 모간 스탠리 제22회 글로벌 헬스케어 컨퍼런스에 참석할 예정입니다. CFO인 이안 소마이야는 9월 5일 투자자들과 1대1로 미팅을 갖고, 9월 6일 오전 10시에 파이어사이드 채팅에 참여할 것입니다.
회사는 2024년 9월 17일 뉴욕시에서 열리는 칸토 글로벌 헬스케어 컨퍼런스에도 참석할 예정입니다. CEO 마이클 데이비슨, M.D.와 CFO 이안 소마이야가 오후 3시 40분에 파이어사이드 채팅에 참여할 것입니다.
두 이벤트의 라이브 웹 캐스트는 NewAmsterdam Pharma의 투자자 관계 페이지에서 제공되며, 이후 다시 보기 기능도 이용할 수 있습니다.
NewAmsterdam Pharma (Nasdaq: NAMS), une entreprise biopharmaceutique en phase avancée axée sur le développement de traitements oraux non statiniques pour les patients atteints de maladies cardiovasculaires (CVD) avec un taux élevé de LDL-C, a annoncé sa participation à des conférences pour investisseurs prévues en septembre.
La direction assistera à la 22e Conférence Mondiale sur la Santé de Morgan Stanley à New York les 5 et 6 septembre 2024. Le CFO Ian Somaiya rencontrera des investisseurs en tête-à-tête le 5 septembre et participera à une discussion informelle le 6 septembre à 10h00 ET.
L'entreprise sera également présente à la Cantor Global Healthcare Conference à New York le 17 septembre 2024. Le CEO Michael Davidson, M.D., et le CFO Ian Somaiya participeront à une discussion informelle à 15h40 ET.
Des webinaires en direct des deux événements seront disponibles sur la page des relations avec les investisseurs de NewAmsterdam Pharma, avec des rediffusions accessibles par la suite.
NewAmsterdam Pharma (Nasdaq: NAMS), ein biopharmazeutisches Unternehmen in der letzten Phase der klinischen Entwicklung, das sich auf die Entwicklung von oralen, nicht-statinischen Behandlungen für Patienten mit Herz-Kreislauf-Erkrankungen (CVD) und hohem LDL-C konzentriert, gab seine Teilnahme an bevorstehenden Investorenkonferenzen im September bekannt.
Das Management wird am 5. und 6. September 2024 an der 22. jährlichen Global Healthcare Conference von Morgan Stanley in New York City teilnehmen. CFO Ian Somaiya wird am 5. September 1:1-Gespräche mit Investoren führen und am 6. September um 10:00 Uhr ET an einem Fireside Chat teilnehmen.
Das Unternehmen wird auch am 17. September 2024 auf der Cantor Global Healthcare Conference in New York City vertreten sein. CEO Michael Davidson, M.D., und CFO Ian Somaiya werden um 15:40 Uhr ET an einem Fireside Chat teilnehmen.
Live-Webcasts beider Veranstaltungen werden auf der Investor-Relations-Seite von NewAmsterdam Pharma verfügbar sein, mit anschließend abrufbaren Wiederholungen.
- None.
- None.
NAARDEN, The Netherlands and MIAMI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:
- Morgan Stanley 22nd Annual Global Healthcare Conference in New York City, NY. Company management will host 1x1 meetings on Thursday, September 5, 2024, and Ian Somaiya, Chief Financial Officer, will participate in a fireside chat on Friday, September 6, 2024, at 10:00 a.m. ET; and
- Cantor Global Healthcare Conference in New York City, NY on Tuesday, September 17, 2024. Michael Davidson, M.D., Chief Executive Officer, and Ian Somaiya, Chief Financial Officer, will participate in a fireside chat at 3:40 p.m. ET.
Live webcasts of both presentations will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company’s website.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
Media Contact
Spectrum Science on behalf of NewAmsterdam
Bryan Blatstein
P: 1-917-714-2609
bblatstein@spectrumscience.com
Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com
FAQ
What upcoming investor conferences will NewAmsterdam Pharma participate in?
When will NewAmsterdam Pharma's CFO Ian Somaiya participate in a fireside chat?
Who will represent NewAmsterdam Pharma at the Cantor Global Healthcare Conference?
Where can I watch the live webcast of NewAmsterdam Pharma's investor presentations?
What is the stock symbol for NewAmsterdam Pharma?
